文献速递临床试验与 GCP

WILL(妊娠期高血压何时引产以降低风险):一项多中心随机对照试验——在COVID-19国际大流行期间调整实施以分娩时机为干预的试验

WILL (When to Induce Labour to Limit risk in pregnancy hypertension): a multicentre randomised controlled trial - adaptations to deliver a timing-of-birth trial during the COVID-19 international pandemic.
PubMed 文献 · Trials · 2022-10-21

WILL是一项实用的分娩时机随机对照试验,因COVID-19大流行调整了试验流程。试验于2020年3月暂停、7月重启,目前在37个英国NHS顾问主导的产科病房招募。调查显示多数中心希望保留远程启动访视、远程知情同意和远程数据监查等灵活策略。

要点

  • 88%中心偏好电子研究者现场文件,但受信息技术要求和临床试验单位操作规程限制仍用纸质文件。
  • 50%中心偏好远程启动访视,44%认为取决于试验类型,少数偏好现场启动访视作为标准程序。
  • 30/37中心使用远程知情同意,涉及54/156名招募者,86%使用该方式的中心认为改善了招募。

核心结论

  • COVID-19疫情对WILL试验流程的调整改善了中心工作人员和参与者的试验实施灵活性,作者认为大流行后应保留使用这些策略的灵活性。

研究设计与样本

  • WILL是一项实用的随机分娩时机试验,试验(内部预试验)于2020年3月暂停、2020年7月重启,目前在37个英国NHS顾问主导的产科病房招募。
  • 研究评估了WILL流程的疫情调整,并通过视频会议调查20个中心对这些变化的看法。

主要发现

  • 尽管88%中心偏好电子研究者现场文件,但信息技术要求和临床试验单位操作规程强制继续使用纸质研究者现场文件,中心启动延迟源于临床试验单位访问受限。
  • 启动访视远程进行,50%中心偏好远程启动访视,44%认为取决于试验类型,少数偏好现场启动访视作为标准程序。
  • 中央团队认为远程启动访视提供了日程和出席灵活性、可录制讨论供缺席或未来工作人员使用、多中心同时参加提高效率并节省时间和成本,对建立融洽关系和互动的不利影响随时间因更熟悉技术和新工作方式而部分缓解。
  • 开发了两种远程知情同意方法,30/37中心使用,涉及54/156名招募者,86%使用远程知情同意的中心认为改善了招募。
  • 远程数据监查(5个中心)的优势主要针对监查员(如灵活性、无时间限制、降低成本),劣势主要针对中心(如文件和访问准备、参加后续会议),但81%中心希望大流行后保留远程监查选项。

临床怎么用

  • 作者认为大流行后应保留使用远程启动访视、远程知情同意和远程数据监查等策略的灵活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As a pragmatic randomised timing-of-birth trial, WILL adapted its trial procedures in response to the COVID-19 pandemic. These are reviewed here to inform post-pandemic trial methodology. METHODS: The trial (internal pilot) paused in March 2020, re-opened in July 2020, and is currently recruiting in 37 UK NHS consultant-led maternity units. We evaluated pandemic adaptations made to WILL processes and surveyed sites for their views of these changes (20 sites, videoconference). RESULTS: Despite 88% of sites favouring an electronic investigator site file (ISF), information technology requirements and clinical trial unit (CTU) operating procedures mandated the ongoing use of paper ISFs; site start-up delays resulted from restricted access to the CTU. Site initiation visits (SIVs) were conducted remotely; 50% of sites preferred remote SIVs and 44% felt that it was trial-dependent, while few preferred SIVs in-person as standard procedure. The Central team felt remote SIVs provided scheduling and attendance flexibility (for sites and trial staff), the option of recording discussions for missing or future staff, improved efficiency by having multiple sites attend, and time and cost savings; the negative impact on rapport-building and interaction was partially mitigated over time with more familiarity with technology and new ways-of-working. Two methods of remote consent were developed and used by 30/37 sites and for 54/156 recruits. Most (86%) sites using remote consenting felt it improved recruitment. For remote data monitoring (5 sites), advantages were primarily for the monitor (e.g. flexibility, no time constraints, reduced cost), and disadvantages primarily for the sites (e.g. document and access preparation, attendance at a follow-up meeting), but 81% of sites desired having the option of remote monitoring post-pandemic. CONCLUSIONS: COVID adaptations to WILL trial processes improved the flexibility of trial delivery, for Central and site staff, and participants. Flexibility to use these strategies should be retained post-pandemic. TRIAL REGISTRATION: ISRCTN77258279. Registered on 05 December 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Magee LA, Tohill S, Kirkham K, et al. WILL (When to Induce Labour to Limit risk in pregnancy hypertension): a multicentre randomised controlled trial - adaptations to deliver a timing-of-birth trial during the COVID-19 international pandemic. Trials. 2022. PMID: 36271441. doi:10.1186/s13063-022-06834-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。